<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05067348</url>
  </required_header>
  <id_info>
    <org_study_id>V3.0, 20210618</org_study_id>
    <nct_id>NCT05067348</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis</brief_title>
  <acronym>tMG</acronym>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tang-Du Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label&#xD;
      extension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled study, to be conducted at 6&#xD;
      study sites. Approximately 64 subjects will be enrolled. Patients with MG who are positive&#xD;
      for anti-AChR antibodies will be enrolled. Patients who do not have anti-AChR or anti-MuSK&#xD;
      antibodies will not be enrolled. Patients with MGFA classification II, III, or IV disease,&#xD;
      MG-ADL score ≥ 5, QMG score ≥ 11, and use of a corticosteroid and/or non-steroidal&#xD;
      immunosuppressant will be included in the study.&#xD;
&#xD;
      All subjects who complete the randomized controlled period will have the option to enroll in&#xD;
      a 1-year open-label period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quantitative Myasthenia Gravis (QMG) scores.</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with both (1) ≥ 3-point improvement in QMG and (2) lasts ≥4 weeks</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with both (1) ≥ 2-point improvement in MG-ADL and (2) lasts ≥4 weeks</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Profile score.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Myasthenia Gravis Composite (MGC) score</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Myasthenia Gravis Quality of Life-15, revised (MGQOL-15r) score.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Myasthenia Gravis Impairment Index (MGII) score.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and treatment-emergent serious adverse events (TESAEs) during the randomized controlled period and open-label period.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Myasthenia Gravis, Generalized</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tocilizumab administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo administered intravenously (IV) on weeks 1,5,9 and 13 of the randomized controlled period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab Injectable Product</intervention_name>
    <description>Participants will receive IV tocilizumab</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of MG with anti-AChRantibody.&#xD;
&#xD;
          2. MGFA Clinical Classification Class II, III, or IV.&#xD;
&#xD;
          3. MG-ADL score of 5 or greater at screening and at randomization with &gt; 50% of this&#xD;
             score attributed to non-ocular items.&#xD;
&#xD;
          4. QMG score of 11 or greater.&#xD;
&#xD;
          5. Subjects must be on:&#xD;
&#xD;
               1. Cholinesterase inhibitor, with no dose increase within 4 weeks prior to&#xD;
                  randomization;&#xD;
&#xD;
               2. Corticosteroids, with no dose increase within 4 weeks prior to randomization;&#xD;
                  or/and c. non-steroidal IST (including azathioprine, mycophenolate mofetil,&#xD;
                  tacrolimus, cyclosporine A), with continuous use for at least 6 months prior to&#xD;
                  randomization and no dose increase within 4 months prior to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants had clinically relevant active infections (such as sepsis, pneumonia, or&#xD;
             abscess) or severe infections (resulting in hospitalization or requiring antibiotic&#xD;
             treatment) in the 4 weeks before randomization;&#xD;
&#xD;
          2. Those with a history of high-risk tuberculosis infection, acquired tuberculosis&#xD;
             infection, and chronic hepatitis;&#xD;
&#xD;
          3. Human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          4. Thymomas that have received thymectomy or planned thymectomy during RCP within 6&#xD;
             months before randomization, or require chemotherapy and/or radiotherapy at any time;&#xD;
&#xD;
          5. Received rituximab treatment in the past 6 months before randomization;&#xD;
&#xD;
          6. Received tocilizumab or eculizumab treatment within 3 months before randomization;&#xD;
&#xD;
          7. Received IVIG or plasma exchange within 4 weeks before randomization;&#xD;
&#xD;
          8. Unresected thymoma.&#xD;
&#xD;
          9. History of other tumor diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting Chang, MD,PHD</last_name>
    <role>Study Director</role>
    <affiliation>The Second Affiliated Hospital of Air Force Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting Chang, MD,PHD</last_name>
    <phone>+86-29-84778845</phone>
    <email>changting1981@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhe Ruan</last_name>
    <phone>+86-29-84778845</phone>
    <email>ruanzhe573291596@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fudong Shi, MD,PHD</last_name>
      <phone>+86-22-60817429</phone>
      <email>fshi@tmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chongbo Zhao, MD,PHD</last_name>
      <phone>86-21-52889999</phone>
      <email>zhao_chongbo@fudan.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin medical university general hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chao Zhang, MD,PHD</last_name>
      <phone>+86-22-60362255</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Generalized Myasthenia Gravis</keyword>
  <keyword>Tocilizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

